CY1121722T1 - Μεθοδοι για την παρασκευη μιας ενωσης διαρυλθειοϋδαντοϊνης - Google Patents

Μεθοδοι για την παρασκευη μιας ενωσης διαρυλθειοϋδαντοϊνης

Info

Publication number
CY1121722T1
CY1121722T1 CY20191100375T CY191100375T CY1121722T1 CY 1121722 T1 CY1121722 T1 CY 1121722T1 CY 20191100375 T CY20191100375 T CY 20191100375T CY 191100375 T CY191100375 T CY 191100375T CY 1121722 T1 CY1121722 T1 CY 1121722T1
Authority
CY
Cyprus
Prior art keywords
compound
preparation
methods
diarylthioyadantoin
intermediates
Prior art date
Application number
CY20191100375T
Other languages
English (en)
Inventor
Cyril Ben HAIM
Andras Horvath
Johan Erwin Edmond Weerts
Jennifer Albaneze-Walker
Original Assignee
Aragon Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aragon Pharmaceuticals, Inc. filed Critical Aragon Pharmaceuticals, Inc.
Publication of CY1121722T1 publication Critical patent/CY1121722T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0235—Nitrogen containing compounds
    • B01J31/0237—Amines
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0255—Phosphorus containing compounds
    • B01J31/0267—Phosphines or phosphonium compounds, i.e. phosphorus bonded to at least one carbon atom, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, the other atoms bonded to phosphorus being either carbon or hydrogen
    • B01J31/0268—Phosphonium compounds, i.e. phosphine with an additional hydrogen or carbon atom bonded to phosphorous so as to result in a formal positive charge on phosphorous
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2409—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/26—Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups B01J31/02 - B01J31/24
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/61—Carboxylic acid nitriles containing cyano groups and nitrogen atoms being part of imino groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/30—Addition reactions at carbon centres, i.e. to either C-C or C-X multiple bonds
    • B01J2231/32—Addition reactions to C=C or C-C triple bonds
    • B01J2231/321—Hydroformylation, metalformylation, carbonylation or hydroaminomethylation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/02—Compositional aspects of complexes used, e.g. polynuclearity
    • B01J2531/0202—Polynuclearity
    • B01J2531/0205—Bi- or polynuclear complexes, i.e. comprising two or more metal coordination centres, without metal-metal bonds, e.g. Cp(Lx)Zr-imidazole-Zr(Lx)Cp
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/824—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Abstract

Αποκαλυπτόμενες είναι μέθοδοι και ενδιάμεσα για την παρασκευή ένωσης (Χ), η οποία σήμερα είναι υπό έρευνα για τη θεραπεία καρκίνου του προστάτη.
CY20191100375T 2014-12-19 2019-04-04 Μεθοδοι για την παρασκευη μιας ενωσης διαρυλθειοϋδαντοϊνης CY1121722T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462094425P 2014-12-19 2014-12-19
PCT/US2015/066345 WO2016100645A1 (en) 2014-12-19 2015-12-17 Processes for the preparation of a diarylthiohydantoin compound

Publications (1)

Publication Number Publication Date
CY1121722T1 true CY1121722T1 (el) 2020-07-31

Family

ID=55221505

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100375T CY1121722T1 (el) 2014-12-19 2019-04-04 Μεθοδοι για την παρασκευη μιας ενωσης διαρυλθειοϋδαντοϊνης

Country Status (33)

Country Link
US (3) US10316015B2 (el)
EP (1) EP3233823B1 (el)
JP (2) JP6696986B2 (el)
KR (1) KR102586087B1 (el)
CN (2) CN107108553B (el)
AR (1) AR103230A1 (el)
AU (2) AU2015364612B2 (el)
BR (1) BR112017013093B1 (el)
CA (1) CA2970933C (el)
CY (1) CY1121722T1 (el)
DK (1) DK3233823T3 (el)
EA (1) EA029666B1 (el)
ES (1) ES2719616T3 (el)
HR (1) HRP20190583T1 (el)
HU (1) HUE042349T2 (el)
IL (2) IL252844B (el)
LT (1) LT3233823T (el)
MA (1) MA41203B1 (el)
MD (1) MD3233823T2 (el)
ME (1) ME03354B (el)
MX (2) MX2017008178A (el)
NZ (1) NZ732756A (el)
PH (1) PH12017501151A1 (el)
PL (1) PL3233823T3 (el)
PT (1) PT3233823T (el)
RS (1) RS58428B1 (el)
SG (2) SG11201704970RA (el)
SI (1) SI3233823T1 (el)
TR (1) TR201904788T4 (el)
TW (3) TWI690520B (el)
UA (1) UA122404C2 (el)
WO (1) WO2016100645A1 (el)
ZA (1) ZA201704878B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE042349T2 (hu) * 2014-12-19 2019-06-28 Aragon Pharmaceuticals Inc Eljárás diariltiohidantoin vegyület elõállítására
CA3077383A1 (en) 2017-09-29 2019-04-04 Sunshine Lake Pharma Co., Ltd. Substituted pyrimidine piperazine compound and use thereof
US10513504B2 (en) 2018-03-08 2019-12-24 Apotex Inc. Processes for the preparation of apalutamide and intermediates thereof
CN108314646B (zh) * 2018-04-11 2021-03-19 武汉慧敏科技中心 一种高分散双金属纳米材料制备泌尿生殖系统用药物中间体的方法
CN111233768B (zh) * 2020-03-18 2021-08-03 徐州圣元化工有限公司 一种3-(二氟甲基)-1-甲基-1h-吡唑-4-羧酸乙酯的制备方法
WO2022049265A1 (en) 2020-09-04 2022-03-10 Synthon B.V. Improved process for preparation of apalutamide
CN114621109B (zh) * 2020-12-14 2024-04-26 成都苑东生物制药股份有限公司 一种阿帕他胺的合成方法及其中间体
CN115650954A (zh) * 2022-10-24 2023-01-31 江苏海悦康医药科技有限公司 阿帕他胺有关物质的制备方法
CN116082246B (zh) * 2022-12-31 2023-11-21 长沙泽达医药科技有限公司 一种乙撑硫脲衍生物的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3412290B1 (en) * 2006-03-27 2021-03-03 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
US8461343B2 (en) * 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
CA2782885A1 (en) * 2009-12-21 2011-07-14 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
SI3124481T1 (en) * 2010-02-16 2018-06-29 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and their use
US9708289B2 (en) * 2013-05-29 2017-07-18 Hinova Pharmaceuticals Inc. Imidazole diketone compound and use thereof
CN103896847B (zh) * 2014-04-09 2016-01-20 沈江 一种非甾体类抗雄激素化合物及其制备方法和应用
HUE042349T2 (hu) * 2014-12-19 2019-06-28 Aragon Pharmaceuticals Inc Eljárás diariltiohidantoin vegyület elõállítására
WO2016100652A2 (en) * 2014-12-19 2016-06-23 Aragon Pharmaceuticals, Inc. Process for the preparation of a diarylthiohydantoin compound

Also Published As

Publication number Publication date
ZA201704878B (en) 2019-02-27
CA2970933A1 (en) 2016-06-23
NZ732756A (en) 2023-02-24
JP2018507170A (ja) 2018-03-15
BR112017013093A2 (pt) 2018-02-20
US10316015B2 (en) 2019-06-11
EA029666B1 (ru) 2018-04-30
TW202016086A (zh) 2020-05-01
SG10201907094QA (en) 2019-09-27
TWI768716B (zh) 2022-06-21
MA41203A (fr) 2017-10-25
KR20170098870A (ko) 2017-08-30
TWI731512B (zh) 2021-06-21
MX2019012734A (es) 2019-12-05
TW202124372A (zh) 2021-07-01
UA122404C2 (uk) 2020-11-10
CN111620849B (zh) 2023-11-14
SI3233823T1 (sl) 2019-04-30
RS58428B1 (sr) 2019-04-30
SG11201704970RA (en) 2017-07-28
ME03354B (me) 2019-10-20
TWI690520B (zh) 2020-04-11
CN111620849A (zh) 2020-09-04
TW201632509A (zh) 2016-09-16
US10723714B2 (en) 2020-07-28
BR112017013093B1 (pt) 2023-03-14
US20190284156A1 (en) 2019-09-19
PH12017501151A1 (en) 2017-11-27
EP3233823B1 (en) 2019-01-30
IL252844A0 (en) 2017-08-31
US11040953B2 (en) 2021-06-22
HRP20190583T1 (hr) 2019-05-17
JP2020143070A (ja) 2020-09-10
PT3233823T (pt) 2019-05-20
AU2015364612A1 (en) 2017-07-06
PL3233823T3 (pl) 2019-07-31
ES2719616T3 (es) 2019-07-11
AU2015364612B2 (en) 2020-06-11
AR103230A1 (es) 2017-04-26
DK3233823T3 (en) 2019-04-08
CN107108553A (zh) 2017-08-29
HUE042349T2 (hu) 2019-06-28
KR102586087B1 (ko) 2023-10-05
US20180002309A1 (en) 2018-01-04
IL281292B1 (en) 2023-03-01
EP3233823A1 (en) 2017-10-25
EA201791391A1 (ru) 2017-10-31
IL252844B (en) 2021-03-25
MX2017008178A (es) 2018-03-06
TR201904788T4 (tr) 2019-04-22
MD3233823T2 (ro) 2019-07-31
US20200354334A1 (en) 2020-11-12
US20190135775A9 (en) 2019-05-09
AU2020227093A1 (en) 2020-09-24
IL281292A (en) 2021-04-29
CN107108553B (zh) 2020-04-28
JP6696986B2 (ja) 2020-05-20
LT3233823T (lt) 2019-04-10
IL281292B2 (en) 2023-07-01
CA2970933C (en) 2023-10-10
WO2016100645A1 (en) 2016-06-23
MA41203B1 (fr) 2019-05-31

Similar Documents

Publication Publication Date Title
CY1123611T1 (el) Μεθοδος για την παρασκευη μιας ενωσης διαρυλθειοϋδαντοϊνης
CY1121722T1 (el) Μεθοδοι για την παρασκευη μιας ενωσης διαρυλθειοϋδαντοϊνης
CY1123598T1 (el) Μακροκυκλικα πεπτιδια χρησιμα ως ανοσοδιαμορφωτες
CO2017004516A2 (es) Anticuerpos anti-ox40 humanizados
CY1121704T1 (el) Μεθοδος για μη-παρεμβατικη αξιολογηση γενετικων παραλλαγων
CY1122803T1 (el) Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων
CY1123581T1 (el) Νεες μεθοδοι για την παραγωγη ολιγονουκλεοτιδιων
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
CY1123906T1 (el) Αναστολεις απομεθυλασης ιστονης
EA201700464A1 (ru) Производные майтанзиноида, их конъюгаты и способы использования
DK3469425T3 (da) Strålingskilde
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
BR112017004444A2 (pt) novos anticorpos anti-mfi2 e métodos de uso
CY1123425T1 (el) Ειδικα για ton rsv αντισωματα και λειτουργικα τμηματα αυτων
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
DK3688530T3 (da) Strålingskilde
BR112017019176A2 (pt) processos para a preparação de fluorocetolídeos
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso
DK3576740T3 (da) Cancerbehandling
DK3407909T3 (da) Cancerbehandling
BR112018012883A2 (pt) novos anticorpos anti-upk1b e métodos de uso
EA201992022A1 (ru) Терапевтическая рнк
BR112017010627A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças